Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey.
Prabhash K, Parikh PM, Rajappa SJ, Noronha V, Joshi A, Aggarwal S, Bondarde S, Patil S, Desai C, Dattatreya PS, Naik R, Anand S, Chacko RT, Biswas G, Sahoo TP, Dabkara D, Patil V, Chandrakant MV, Das PK, Vaid AK, Doval DC. Prabhash K, et al. Among authors: sahoo tp. South Asian J Cancer. 2018 Jul-Sep;7(3):203-206. doi: 10.4103/sajc.sajc_30_18. South Asian J Cancer. 2018. PMID: 30112342 Free PMC article.
ICON 2013: practical consensus recommendations for hormone receptor-positive Her2-negative advanced or metastatic breastcancer.
Parikh PM, Gupta S, Dawood S, Rugo H, Bhattacharyya GS, Agarwal A, Chacko R, Sahoo TP, Babu G, Agarwal S, Munshi A, Goswami C, Smruti BK, Bondarde S, Desai C, Rajappa S, Somani N, Singh M, Nimmagadda R, Pavitran K, Mehta A, Parmar V, Desai S, Nair R, Doval D. Parikh PM, et al. Among authors: sahoo tp. Indian J Cancer. 2014 Jan-Mar;51(1):73-9. doi: 10.4103/0019-509X.134650. Indian J Cancer. 2014. PMID: 24947101 Free article.
Advanced therapeutic options and importance of rebiopsy in epidermal growth factor receptor-tyrosine kinase inhibitor-progressed nonsmall cell lung carcinoma patients: An expert opinion.
Advani SH, Malhotra H, Chacko RT, Basade M, Keechilat P, Mahapatra PN, Goswami C, Sahoo TP, Shah C. Advani SH, et al. Among authors: sahoo tp. Indian J Cancer. 2017 Dec;54(Supplement):S31-S36. doi: 10.4103/ijc.IJC_520_17. Indian J Cancer. 2017. PMID: 29292706 Free article. Review.
Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method.
Parikh P, Babu G, Singh R, Krishna V, Bhatt A, Bansal I, Rajappa S, Sahoo TP, Aggarwal S, Bapna A, Biswas G, Somashekhar SP, Bajpai J, Maniar V, Desai S, Raja T, Rath GK. Parikh P, et al. Among authors: sahoo tp. BMC Cancer. 2023 Jul 31;23(1):714. doi: 10.1186/s12885-023-11121-9. BMC Cancer. 2023. PMID: 37525142 Free PMC article.
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Gradishar WJ, Kaklamani V, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M, Ro SK, Lokker NA, Schwartzberg L. Gradishar WJ, et al. Among authors: sahoo tp. Eur J Cancer. 2013 Jan;49(2):312-22. doi: 10.1016/j.ejca.2012.08.005. Epub 2012 Sep 3. Eur J Cancer. 2013. PMID: 22954665 Clinical Trial.
Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.
Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Frimodt-Moller B, Koustenis A, Hong RL. Urba S, et al. Among authors: sahoo tp. Cancer. 2012 Oct 1;118(19):4694-705. doi: 10.1002/cncr.27449. Epub 2012 Mar 20. Cancer. 2012. PMID: 22434360 Free article. Clinical Trial.
34 results